Biological Products, (No Disgnostic Substances)

Search by Letter:

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9

Vericel Corporation

Aastrom Biosciences, Inc., a regenerative medicine company, engages in developing autologous cell therapies for the treatment of severe and chronic cardiovascular diseases. The company’s autologous expanded cellular therapy technology uses single-pass perfusion to produce human cell products for clinical use. Its clinical development programs include CLI program, which is in phase IIb clinical ... more

Acorda Therapeutics, Inc.

Acorda Therapeutics, Inc., a commercial stage biopharmaceutical company, involves in the identification, development, and commercialization of therapies for multiple sclerosis (MS), spinal cord injury, and other nervous system disorders. Its marketed products include Ampyra (dalfampridine), a potassium channel blocker for improving walking in patients with MS; and Zanaflex Capsules and ... more

Agenus Inc.

Agenus Inc., a biotechnology company, engages in developing and commercializing technologies to treat cancers and infectious diseases. It offers Oncophage vaccine for the treatment of adjuvant renal cell carcinoma. The company’s products under development include Prophage series of cancer vaccines, which has been tested in Phase III clinical trials for the treatment of renal cell carcinoma ... more

Amgen Inc.

Amgen Inc., a biotechnology medicines company, discovers, develops, manufactures, and markets human therapeutics based on advances in cellular and molecular biology for grievous illnesses primarily in the United States, Europe, and Canada. The company markets recombinant protein therapeutics in supportive cancer care, nephrology, and inflammation. Its principal products include Aranesp and ... more

ARIAD Pharmaceuticals, Inc.

ARIAD Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small-molecule drugs for the treatment of cancer. The company’s lead cancer product, ridaforolimus is being studied in multiple clinical trials in patients with various types of cancers, including metastatic sarcomas, breast cancer, endometrial cancer, prostate cancer, and ... more

BioCryst Pharmaceuticals, Inc.

BioCryst Pharmaceuticals, Inc., a biotechnology company, designs, optimizes, and develops small-molecule pharmaceuticals that block key enzymes involved in infectious diseases, cancer, and inflammatory diseases. It uses structure-based drug design, which incorporates multiple scientific disciplines, including biology, crystallography, medicinal chemistry, and computer to develop new ... more

Biogen Idec Inc

Biogen Idec Inc. discovers, develops, manufactures, and markets therapeutics in the areas of neurology, immunology, hemophilia, and oncology in the United States and internationally. Its marketed products include AVONEX for the treatment of relapsing multiple sclerosis (MS); RITUXAN for treating relapsed or refractory, CD20-positive, and B-cell Non-Hodgkin’s Lymphoma (NHL); TYSABRI to treat ... more

ANI Pharmaceuticals, Inc.

BioSante Pharmaceuticals, Inc., a specialty pharmaceutical company, develops products for female sexual health and oncology. Its lead products include LibiGel (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD), which is in Phase III clinical development under a U.S. Food and Drug Administration (FDA) special protocol assessment; and Elestrin (estradiol gel) for ... more

Chelsea Therapeutics International, Ltd.

Chelsea Therapeutics International, Ltd., a development-stage pharmaceutical company, focuses on the acquisition, development, and commercialization of therapeutic products for the treatment of various human diseases. It is involved in developing Droxidopa, a therapeutic agent for the treatment of symptomatic neurogenic orthostatic hypotension (NOH) associated with primary autonomic failure ... more

China Biologic Products, Inc.

China Biologic Products, Inc., through its subsidiaries, engages in the research, development, manufacturing, and sale of plasma-based pharmaceutical products. It provides Human Albumin for the treatment of shock caused by blood loss trauma or burn; raised intracranial pressure caused by hydrocephalus or trauma; oedema or ascites caused by hepatocirrhosis and nephropathy; and Neonatal ... more

Compugen Ltd.

Compugen Ltd. operates as a drug and diagnostic discovery company based on computer-based discovery capabilities to predict and select novel product candidates. Through in silico prediction and selection, the resulting novel molecules are synthesized and validated utilizing traditional in vitro and in vivo experimental procedures. The company provides these validated product candidates to ... more

Curis, Inc.

Curis, Inc., a drug discovery and development company, engages in the research and development of cancer therapeutics. The company develops GDC-0449, an orally-administered small molecule Hedgehog pathway inhibitor, which is under pivotal phase II trial in advanced basal cell carcinoma patients, and a phase II clinical trial in operable nodular basal cell carcinoma patients. It also develops ... more

CytRx Corporation

CytRx Corporation, a biopharmaceutical research and development company, engages in the development of human therapeutics, specializing in oncology. The company’s drug development pipeline includes clinical development of three product candidates for cancer indications, including three planned Phase II clinical trials for INNO-206 as a treatment for pancreatic cancer, gastric (stomach) cancer, ... more

Discovery Laboratories, Inc.

Discovery Laboratories, Inc., a biotechnology company, engages in developing surfactant and aerosol drug delivery technologies for the treatment of respiratory disorders and other diseases based on KL4 surfactant and capillary aerosol-generating technologies. The company’s product pipeline includes Surfaxin, a synthetic, peptide-containing surfactant that completed Phase-III clinical trial for ... more

CASI Pharmaceuticals, Inc.

Entremed, Inc., a clinical-stage pharmaceutical company, engages in developing therapeutics for the treatment of cancer and inflammatory diseases. It is developing primarily ENMD-2076, an Aurora A and angiogenic kinase inhibitor for the treatment of cancer. ENMD-2076 is in Phase 1 studies in multiple myeloma and a multi-center, and Phase 2 studies in patients with platinum resistant ovarian ... more